Amarin Corp. fell to the lowest since March after it lost its bid to revive patents on the heart medicine Vascepa, its only product, a decision that opens the door to generic competition for the drug.
The U.S. Court of Appeals for the Federal Circuit in Washington affirmed a trial court ruling that invalidated six patents on Vascepa. The decision, made without a formal opinion, came just one day after the court heard arguments in the case.
